Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome (SS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04129164
Recruitment Status : Recruiting
First Posted : October 16, 2019
Last Update Posted : October 1, 2021
Sponsor:
Information provided by (Responsible Party):
Viela Bio

Tracking Information
First Submitted Date  ICMJE October 2, 2019
First Posted Date  ICMJE October 16, 2019
Last Update Posted Date October 1, 2021
Actual Study Start Date  ICMJE October 16, 2019
Estimated Primary Completion Date February 18, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 14, 2019)
  • Change From Baseline in European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) at Day 169 in Population 1 [ Time Frame: Baseline (Day 1) and Day 169 ]
  • Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) at Day 169 in Population 2 [ Time Frame: Baseline (Day 1) and Day 169 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 14, 2019)
  • Change From Baseline in ESSPRI at Day 169 in Population 1 [ Time Frame: Baseline (Day 1) and Day 169 ]
  • Percentage of Participants achieving ESSDAI [3] and ESSDAI [4] response in Population 1 [ Time Frame: Baseline (Day 1) to Day 169 ]
  • Percentage of Participants achieving ESSPRI response in Population 2 [ Time Frame: Baseline (Day 1) to Day 169 ]
  • Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score at Day 169 in Populations 1 and 2 [ Time Frame: Baseline (Day 1) and Day 169 ]
  • Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169 in Populations 1 and 2 [ Time Frame: Baseline (Day 1) and Day 169 ]
  • Patient's Global Impression of Severity at Day 169 in Populations 1 and 2 [ Time Frame: Day 169 ]
  • Number of participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Populations 1 and 2 [ Time Frame: From Baseline (Day 1) up to Day 365 ]
  • Number of participants With Adverse Events of Special Interest (AESIs) in Populations 1 and 2 [ Time Frame: From Baseline (Day 1) up to Day 365 ]
  • Number of Participants With Abnormal Laboratory Parameters, Vital Signs, and Electrocardiograms (ECGs) Reported as TEAEs in Populations 1 and 2 [ Time Frame: From Baseline (Day 1) up to Day 365 ]
  • Plasma Concentration of VIB4920 [ Time Frame: Day 1 to Day 365 ]
  • Percentage of Participants With Positive Antibody Titer to VIB4920 in Populations 1 and 2 [ Time Frame: Day 1 to Day 365 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
Official Title  ICMJE A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
Brief Summary The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
Detailed Description The study will enrol 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity defined by European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) >= 5; Population 2 will include participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score >= 5 and residual stimulated salivary flow but with mild systemic disease activity defined by ESSDAI score < 5. This study will include 3 periods: screening (4 weeks), treatment period (40 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized at 1:1 ratio to receive intravenous (IV) dose of VIB4920 or placebo (Stage I). After completion of Stage I, participants randomized to VIB4920 in Stage I will receive placebo and participants randomized to placebo in Stage I will receive VIB4920 (Stage II). Participants who had study drug discontinuation will not be eligible for treatment during Stage II. All participants will be followed for at least 12 weeks after their last dose of study drug administration.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Sjögren's Syndrome
Intervention  ICMJE
  • Drug: VIB4920
    Intravenous Dose 1.
  • Drug: Placebo
    Intravenous dose matched to VIB4920.
Study Arms  ICMJE
  • Experimental: VIB4920 Dose 1 in Population 1
    Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
    Interventions:
    • Drug: VIB4920
    • Drug: Placebo
  • Placebo Comparator: Placebo in Population 1
    Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
    Interventions:
    • Drug: VIB4920
    • Drug: Placebo
  • Experimental: VIB4920 Dose 1 in Population 2
    Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
    Interventions:
    • Drug: VIB4920
    • Drug: Placebo
  • Placebo Comparator: Placebo in Population 2
    Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
    Interventions:
    • Drug: VIB4920
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 14, 2019)
174
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 3, 2023
Estimated Primary Completion Date February 18, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR Classification Criteria.
  • Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min (only for Population 2).
  • Have an ESSDAI score of >= 5 at screening; (not including the peripheral nervous system, central nervous system, and pulmonary domains) (only for Population 1).
  • Have an ESSPRI score of >= 5 at screening (only for Population 2).
  • Have an ESSDAI score of < 5 at screening (only for Population 2).
  • Positive for either anti-Ro autoantibodies or rheumatoid factor, or both at screening.
  • Male and female participants who agree to follow protocol defined contraceptive methods.
  • No active or untreated latent tuberculosis (TB).

Exclusion Criteria:

  • Medical history of confirmed deep venous thrombosis or arterial thromboembolism within 2 years of signing the informed consent form (ICF).
  • Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.
  • Concomitant polymyositis or dermatomyositis or systemic sclerosis.
  • Active malignancy or history of malignancy, except in situ carcinoma of the cervix and cutaneous basal cell carcinoma.
  • Hepatitis B, hepatitis C, or human immunodeficiency virus infection.
  • More than one episode of herpes zoster and/or an opportunistic infection in the last 12 months.
  • Active viral, bacterial, or other infections or history of more than 2 infections requiring intravenous antibiotics within 12 months prior to signing the ICF.
  • Participants with corona virus disease 2019 (COVID-19) infection or who, in the judgment of the investigator, are at unacceptable risk of COVID-19 or its complications.
  • A documented positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 2 weeks prior to randomization.
  • Received live (attenuated) vaccine within the 4 weeks prior to ICF signature.
  • Treated with any biologic B-cell-depleting therapy within 12 months or other B-cell targeting therapy < 3 months before randomization.
  • Injectable corticosteroids (including intraarticular) or treatment with > 10 mg/day dose oral prednisone or equivalent within 6 weeks prior to randomization (only for Population 1).
  • Treated with systemic corticosteroids for indications other than SS, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) for more than a total of 2 weeks within 24 weeks prior to screening visit (only for Population 1).
  • Received previous treatment with anti-CD40L compounds at any time before screening.
  • Pregnant or lactating or planning to get pregnant during the duration of the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Study Director 1-866-479-6742 ClinicalTrials@VielaBio.com
Listed Location Countries  ICMJE France,   Hungary,   India,   Italy,   Korea, Republic of,   Mexico,   Peru,   Poland,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04129164
Other Study ID Numbers  ICMJE VIB4920.P2.S2
2019-002713-19 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Viela Bio
Study Sponsor  ICMJE Viela Bio
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Viela Bio
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP